U.S. Food and Drug Administration main campus building. Photo: ALM.
As the U.S. is seeking to sever ties with some Chinese biotech players, a bipartisan group of lawmakers on Tuesday called on the Biden administration to ramp up scrutiny of hundreds of clinical trials conducted by U.S. drug companies with the Chinese military, citing the risk of intellectual property theft, as the nations compete on biotechnology.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
